TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01177371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or orally
Study: NCT00304551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 180μg
Description: 180μg（s.c.）/week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 90μg
Description: 90μg(s.c.)/week for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 600, 800, or 1,000 mg X 2(p.o.)/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 600, 800, or 1,000 mg X 2(p.o.)/day
Study: NCT04948372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin treatment
Description: Patients in the terlipressin group received a fixed dose of terlipressin added to usual care. Terlipressin was intravenously pumped at a fixed dose of 1.3μg/kg/hour for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients in the usual care group were treated with standard care, according to the international guidelines for the management of sepsis and septic shock.
Study: NCT01774396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emervel® Touch
Description: Emervel® Touch will be injected only in the intervention group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine
Description: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.

Intervention type: DRUG
Group type: OTHER
Intervention: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine
Description: Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
Study: NCT02877992

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian puncture
Description: Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
Study: NCT01504490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017 and Bexarotene
Description: CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to.
Study: NCT00268307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous, Unfractionated Bone Marrow Mononuclear Cells
Description: Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
Study: NCT02704364

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT02071394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon gas
Description: Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cooling
Description: Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
Study: NCT03051178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Responsive deep brain stimulation
Description: Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
Study: NCT02622126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (6% 130/0.4)
Description: preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyethyl starch (6% 130/0.4)
Description: preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Sub arachnoid 10-12 mg hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Sub arachnoid 10-12 mg hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Sub arachnoid 200 meg morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Sub arachnoid 200 meg morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic 0.9 sodium chloride (NaCl) solution
Description: 10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic 0.9 sodium chloride (NaCl) solution
Description: 10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
Study: NCT01610687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
Study: NCT00839709

Intervention type: PROCEDURE
Intervention: blood sampling
Description: peripheral blood draw

Intervention type: PROCEDURE
Intervention: blood sampling
Description: peripheral blood draw
Study: NCT02622126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
Study: NCT01022502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: refined indigo naturalis ointment
Description: The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crude indigo naturalis ointment
Description: The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
Study: NCT02863627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Newborn Care Pathway
Description: consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
Study: NCT04557319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-038, 25 МЕ/kg
Description: 25 МЕ/kg once per study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-038, 50 МЕ/kg
Description: 50 МЕ/kg once per study

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNR-038, 100 МЕ/kg
Description: 100 МЕ/kg once per study
Study: NCT02622126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: Bradycardia (fall of \>30% of heart rate from baseline or \<50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
Study: NCT01454102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT00579683

Intervention type: OTHER
Intervention: Tumor core biopsy for RNA isolation
Description: RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
Study: NCT01454102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01148706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiSight Needle Guidance System
Description: The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
Study: NCT03533413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined CT-fluroscopy
Description: Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard fluroscopy
Description: Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
Study: NCT02478905

Intervention type: OTHER
Intervention: Influenza
Study: NCT01454102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT00518427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Lantus (insulin glargine \[rDNA origin\] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment.
Study: NCT02013453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 40mg of Omeprazole will be administered daily by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40mg of Omeprazole will be administered daily by mouth.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered over 30 minutes by continuous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered over 30 minutes by continuous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered over 30 minutes by continuous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: Administered by infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: Administered by infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: Administered by infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered by infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered by infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered by infusion.
Study: NCT03281967

Intervention type: DEVICE
Group type: OTHER
Intervention: Minimally Invasive Ponto Surgery
Description: Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
Study: NCT04862624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Catalina Story-Based Web-App
Description: Latinas in the experimental group will view a story-based web-app featuring a character named Catalina and psycho-therapeutic modules to motivate them to take action and get help for their symptoms of depression and/or anxiety.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Web-App
Description: Latinas in the attention control group will view non-story based media that is informational.
Study: NCT01294150

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift System
Description: The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cystoscopy
Description: The Control Group will undergo cystoscopy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crossover
Description: Subjects crossed over and received the UroLift System from the Control Group.
Study: NCT02770443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: withdrawal
Description: withdrawal of beta blocker and ACE inhibitors

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: standard of CARE
Description: STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
Study: NCT00252304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc (zinc sulphate)
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05110339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexmedetomidine
Description: Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Erector spinae block with ropivacaine at a dose of 0.5%.
Study: NCT04711798

Intervention type: OTHER
Intervention: passive leg raising maneuver (PLR)
Description: Passive leg raising maneuver (PLR) for preload status evaluation using the PICCO system will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).

Intervention type: OTHER
Intervention: lung recruitment maneuver (LRM)
Description: lung recruitment maneuver (LRM) will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).

Intervention type: OTHER
Intervention: echographic evaluation of the right cardiac function
Description: echographic evaluation of the right cardiac function will be realized in Phase 1 (pre operatively), Phase 2 (after the sternotomy closure in the operating room), Phase 3 (H+2 of the arrival in cardiac intensive care unit).
Study: NCT02755168

Intervention type: PROCEDURE
Group type: OTHER
Intervention: External Pop-Out Cesarean Section
Description: During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic technique
Description: During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
Study: NCT01454102

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT01378871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMTOX-25
Description: This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mL contains 2.5 mg IMTOX-25~IMTOX-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.~15 mg/m²/cycle IV. The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7.
Study: NCT04355143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Tablets
Description: COLCRYS (colchicine, USP) tablets for oral administration, containing 0.6 mg of the active ingredient colchicine USP, administered po every 12 hours x 30 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Current care per UCLA treating physicians
Description: Current care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current care per UCLA treating physicians
Description: Current care
Study: NCT02148874

Intervention type: BIOLOGICAL
Intervention: influenza virus vaccination
Description: comparison of immune responses to the flu vaccine in obese and non-obese populations
Study: NCT02724891

Intervention type: OTHER
Intervention: paper form
Description: questionnaires in paper form

Intervention type: OTHER
Intervention: paper form
Description: questionnaires in paper form

Intervention type: OTHER
Intervention: web/smartphone form
Description: questionnaires in web/smartphone

Intervention type: OTHER
Intervention: web/smartphone form
Description: questionnaires in web/smartphone
Study: NCT04349878

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: gingival crevicular fluid evaluation
Description: anaysis of interleukins in gingival crevicular fluid

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: gingival crevicular fluid evaluation
Description: anaysis of interleukins in gingival crevicular fluid
Study: NCT02818166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery
Description: Right mini-thoracotomy mitral valve replacement/repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve surgery
Description: Right mini-thoracotomy mitral valve replacement/repair.